The approval was on the basis of a multi-center, multi-queue clinical trial which demonstrated that the reaction rate of pralsetinib in patients with untreated RET-mutant MTC is 71%, whereas the overall reaction rate in patients with RET fusion-positive thyroid carcinoma receiving radioiodine treatment is 89% [161]. This evidence concerns the gene RET and medullary thyroid gland carcinoma.